Metastatic Uveal Melanoma

Oncology·MeSH: Melanoma

Prevalence

75.0 / 100K

Incidence

23.0 / 100K/yr

9 drugs in development·6 companies·8 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
KIMMTRAK	Immunocore Holdings plc (IMCR)

Phase 3(1)

Drug	Company
cemiplimab	GH Research PLC (GHRS)

Phase 2(2)

Drug	Company
Relatlimab	UNITED THERAPEUTICS Corp (UTHR)
RP2	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1/Phase 2(3)

Drug	Company
Binimetinib	IDEAYA Biosciences, Inc. (IDYA)
IDE196	IDEAYA Biosciences, Inc. (IDYA)
sd-101	TriSalus Life Sciences Inc. (TLSI)

Phase 2/Phase 3(2)

Drug	Company
Crizotinib	IDEAYA Biosciences, Inc. (IDYA)
Dacarbazine	IDEAYA Biosciences, Inc. (IDYA)

BioSniper tracks 9 drugs in development for Metastatic Uveal Melanoma across 6 companies.

There are 8 clinical trials targeting Metastatic Uveal Melanoma tracked by BioSniper.

The estimated prevalence of Metastatic Uveal Melanoma is approximately 75.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.